ANTIBODIES
Patent Information
- Application Number
- ARP20250100858
- Authority / Receiving Office
- AR · AR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-06-24
- Filing Date
- 2025-04-02
- Publication Date
- 2026-10-07
Claims
The present invention relates to antibodies that bind or pair with free light chains, such as free kappa light chains and / or amyloidogenic (kappa) light chains, and formulations comprising them. The invention further relates to the use of the antibodies against light chains and formulations in therapy and / or diagnosis.
1. An antibody that binds specifically to free light chains, such as free kappa light chains and / or amyloidogenic (kappa) light chains, characterized in that the antibody comprises a variable heavy chain region comprising: i. a CDR-H1 consisting of SEQ ID Nos. 1, 4, 7, 10 or 13, a CDR-H2 consisting of SEQ ID Nos. 2, 5, 8, 11 or 14 and a CDR-H3 consisting of SEQ ID Nos. 3, 6, 9, 12 or 15; or ii. a combination of CDR-H1, CDR-H2 and CDR-H3 sequences that have at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity or similarity to any of the sequences listed in i.
3. An antibody that binds specifically to light chains, such as kappa light chains and / or amyloidogenic (kappa) light chains, characterized in that the antibody has a heavy chain variable region comprising any of SEQ ID Nos. 16 to 26 or a sequence having at least 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with it.
10. An isolated polynucleotide characterized in that it encodes the antibody according to any of claims 1 to 9.
11. A cloning or expression vector characterized in that it comprises the polynucleotide according to claim 10.
12. A host cell characterized in that it comprises the polynucleotide according to claim 10 or the expression vector according to claim 11.
13. A process for the production of an antibody according to any of claims 1 to 9, characterized in that it comprises culturing the host cell according to claim 12 under conditions suitable for producing the antibody and isolating the antibody.
14. A pharmaceutical composition characterized in that it comprises the antibody according to any of claims 1 to 9, or a polynucleotide according to claim 10, and one or more pharmaceutically acceptable excipients, diluents and / or carriers.